Breaking News Instant updates and real-time market news.

CRSP

Crispr Therapeutics

$38.71

1.01 (2.68%)

, VRTX

Vertex

$179.48

1.08 (0.61%)

07:10
11/30/18
11/30
07:10
11/30/18
07:10

Crispr Therapeutics initiated with a Buy at Needham

Needham analyst Alan Carr initiated CRISPR Therapeutics (CRSP) with a Buy rating and a price target of $62 based on its position as a "leader in gene editing". The analyst notes that the company is "initially focused on ex vivo applications of the technology associated with reduced technical and safety risks", which he believes to hold "substantial value, particularly in immuno-oncology." Carr adds that with Crispr and collaborator Vertex (VRTX) recently launching a clinical development of CTX-001 in Beta Thalassemia and Sickle Cell Disease, he estimates the company to launch these products in the U.S. in 2022 and 2023, respectively.

CRSP

Crispr Therapeutics

$38.71

1.01 (2.68%)

VRTX

Vertex

$179.48

1.08 (0.61%)

CRSP Crispr Therapeutics
$38.71

1.01 (2.68%)

11/11/18
PIPR
11/11/18
NO CHANGE
Target $75
PIPR
Overweight
Piper Jaffray bullish on Crispr Therapeutics after SITC data
Piper Jaffray analyst Edward Tenthoff notes that Crispr Therapeutics presented a poster at SITC that showed the "impressive" capability of CRISPR/Cas9 to now introduce up to 7 edits to produce an allogeneic CART. The analyst believes the number of edits, unrivaled by other editing modalities, and strong efficiency with 50%-70% rates underscores the robust capabilities offered by CRISPR/Cas9 editing and could diversify the company's CAR-T pipeline in a competitive field. SITC data revealed quadruple-edited cells more potently inhibited tumor growth in vivo versus dual edits, he adds. Tenthoff points out that Crispr Therapeutics expects to initiate a Phase I study on CD19 CAR-T CTX110 in 1H19, with BCMA and CD70 CAR-Ts to follow. First-in-man CTX001 data next year could lead to accelerated approvals by 2021, he contended. The analyst reiterates an Overweight rating and $75 price target on the shares.
10/15/18
PIPR
10/15/18
NO CHANGE
PIPR
Piper lists names to own in Biopharma after recent selloff
Piper Jaffray's biopharma analyst team highlighted names to own in the Biopharma sector following the recent selloff of the broader market. The firm's ideas include: Adamas Pharmaceuticals (ADMS), Agios Pharmaceuticals (AGIO), Agios Pharmaceuticals (ALNY), Alexion (ALXN), Bluebird Bio (BLUE), BioMarin (BMRN), CymaBay (CBAY), Crispr Therapeutics (CRSP), Global Blood Therapeutics (GBT), Horizon Pharma (HZNP), Jazz Pharmaceuticals (JAZZ), Ocular Therapeutix (OCUL), Rigel Pharmaceuticals (RIGL) and Xencor (XNCR).
10/10/18
10/10/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Take-Two (TTWO) initiated with an Outperform at Bernstein. 2. Shake Shack (SHAK) initiated with a Hold at Stifel. 3. Nu Skin (NUS) initiated with a Buy at DA Davidson. 4. Micron (MU) initiated with a Neutral at Piper Jaffray. 5. Crispr Therapeutics (CRSP) initiated with an Outperform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/10/18
WELS
10/10/18
INITIATION
Target $65
WELS
Outperform
Crispr Therapeutics initiated with an Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough started Crispr Therapeutics with an Outperform rating and $65 price target. The analyst cited the company's "highly leverageable" gene editing platform, "substantially de-risked" lead program in ex-vivo gene editing for beta thalassemia and sickle cell disease, a broad pipeline of both ex vivo and in vivo gene-editing opportunities, and strong collaborations balancing wholly owned programs to optimize future value creation.
VRTX Vertex
$179.48

1.08 (0.61%)

11/27/18
PIPR
11/27/18
NO CHANGE
Target $217
PIPR
Overweight
Piper says Vertex's VX-659 achieved 'unprecedented' improvement in trials
After Vertex announced 4-week efficacy and 12-week safety data from two TripleRx Phase 3 trials of VX-659 plus Symdeko, Piper Jaffray analyst Edward Tenthoff said VX-659 achieved "unprecedented" four-week mean absolute improvement in ppFEV1 in both patient populations studied. He anticipates Vertex will file an NDA on the best TripleRx regimen in mid 2019 and currently sees the first TripleRx reaching the market in 2020. Tenthoff keeps an Overweight rating and $217 price target on Vertex shares.
11/26/18
LEHM
11/26/18
NO CHANGE
Target $200
LEHM
Overweight
Vertex risk/reward 'compelling' after 11% selloff, says Barclays
Barclays analyst Geoff Meacham thinks the 11% pullback in shares of Vertex Pharmaceuticals over the last two weeks sets up a "compelling" risk/reward profile going into Phase 3 data for the triple combo in cystic fibrosis at year-end. The stock has now only modestly outperformed year-to-date despite a "robust launch" of Symdeko and Phase 2 de-risking of VX-445 and VX-659 combos, Meacham tells investors in a research note. He keeps an Overweight rating on the shares with a $200 price target.
11/07/18
PIPR
11/07/18
NO CHANGE
Target $14
PIPR
Overweight
Piper Jaffray sees 'huge valuation disconnect' between Proteostasis, Vertex
Piper Jaffray analyst Edward Tenthoff notes that Proteostasis (PTI) ended Q3 with cash of $46M million subsequently completed an equity financing and sold 1.4M shares through an ATM, bringing pro forma cash to about $138M, which he estimates will fund the company into 2020. The primary driver remains initial Phase I data on Proteostasis' proprietary TripleRx regimen in homozygous F508del Cystic Fibrosis this quarter, he contends, adding that he remains encouraged based on recently reported positive Phase I data on proprietary CFTR potentiator PTI-808 and corrector PTI-801 in homozygous F508del CF patients. The analyst sees a "huge valuation disconnect" between Proteostasis and CF market leader Vertex (VRTX), and reiterates an Overweight rating and $14 price target on the former's shares.
11/07/18
CANT
11/07/18
INITIATION
Target $21
CANT
Overweight
Cantor sees 'clear opportunity' for Proteostasis, starts at Overweight
Cantor Fitzgerald analyst Elemer Piros last night initiated coverage of Proteostasis (PTI) with an Overweight rating and $21 price target. Proteostasis is developing CFTR modulator therapies for the treatment of cystic fibrosis, Piros tells investors in a research note. The analyst sees a "clear opportunity" for Proteostasis to carve out a good portion of the market and make a name for itself in CF. Vertex (VRTX) has opened the door for developing CFTR modulators, says Piros.

TODAY'S FREE FLY STORIES

ROK

Rockwell Automation

$200.22

1.32 (0.66%)

06:13
11/18/19
11/18
06:13
11/18/19
06:13
Upgrade
Rockwell Automation rating change  »

Rockwell Automation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 19

    Nov

  • 20

    Nov

VWAGY

Volkswagen

$0.00

(0.00%)

06:13
11/18/19
11/18
06:13
11/18/19
06:13
Hot Stocks
Breaking Hot Stocks news story on Volkswagen »

Volkswagen sees 2020…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEO

Cnooc

$155.34

1.91 (1.24%)

06:13
11/18/19
11/18
06:13
11/18/19
06:13
Hot Stocks
Cnooc appoints Wang Dongjin as chairman »

Cnooc announced Wang…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMGI

Wright Medical

$29.50

0.105 (0.36%)

06:13
11/18/19
11/18
06:13
11/18/19
06:13
Downgrade
Wright Medical rating change  »

Wright Medical downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VWAGY

Volkswagen

$0.00

(0.00%)

06:13
11/18/19
11/18
06:13
11/18/19
06:13
Hot Stocks
Volkswagen confirms strategic financial targets of Together 2025+ »

The Volkswagen Group has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VWAGY

Volkswagen

$0.00

(0.00%)

06:12
11/18/19
11/18
06:12
11/18/19
06:12
Hot Stocks
Volkswagen confirms outlook for 2019 »

The automaker previously…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PH

Parker-Hannifin

$196.59

2.38 (1.23%)

06:12
11/18/19
11/18
06:12
11/18/19
06:12
Initiation
Parker-Hannifin initiated  »

Parker-Hannifin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

EADSY

Airbus

$0.00

(0.00%)

, BA

Boeing

$371.55

4.25 (1.16%)

06:11
11/18/19
11/18
06:11
11/18/19
06:11
Periodicals
Emirates orders 50 Airbus A350 jets worth $16B, Reuters reports »

Emirates has ordered 50…

EADSY

Airbus

$0.00

(0.00%)

BA

Boeing

$371.55

4.25 (1.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OEC

Orion Engineered

$18.77

-0.08 (-0.42%)

06:10
11/18/19
11/18
06:10
11/18/19
06:10
Hot Stocks
Orion Engineered says director Kerry Galvin buys 1,800 common shares »

Orion Engineered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$149.32

1.17 (0.79%)

, EADSY

Airbus

$0.00

(0.00%)

06:09
11/18/19
11/18
06:09
11/18/19
06:09
Periodicals
IndiGo CEO says replacing Pratt engines in fleet 'challenging,' Reuters reports »

IndiGo CEO Ronojoy Dutta…

UTX

United Technologies

$149.32

1.17 (0.79%)

EADSY

Airbus

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KB

KB Financial Group

$37.67

0.305 (0.82%)

06:09
11/18/19
11/18
06:09
11/18/19
06:09
Upgrade
KB Financial Group rating change  »

KB Financial Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$23.99

2.5 (11.63%)

06:09
11/18/19
11/18
06:09
11/18/19
06:09
Downgrade
Citi downgrades Amarin to Neutral, says strong sales growth priced in »

Citi analyst Joel Beatty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

DRNA

Dicerna

$19.29

-0.86 (-4.27%)

, NVO

Novo Nordisk

$57.28

-0.61 (-1.05%)

06:08
11/18/19
11/18
06:08
11/18/19
06:08
Hot Stocks
Dicerna, Novo Nordisk enter pact to develop RNAi therapies »

Dicerna Pharmaceuticals…

DRNA

Dicerna

$19.29

-0.86 (-4.27%)

NVO

Novo Nordisk

$57.28

-0.61 (-1.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

TNK

Teekay Tankers

$2.39

0.155 (6.94%)

06:08
11/18/19
11/18
06:08
11/18/19
06:08
Upgrade
Teekay Tankers rating change  »

Teekay Tankers upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ELS

Equity Lifestyle

$69.44

0.795 (1.16%)

06:05
11/18/19
11/18
06:05
11/18/19
06:05
Upgrade
Equity Lifestyle rating change  »

Equity Lifestyle upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

MU

Micron

$47.70

0.88 (1.88%)

, WDC

Western Digital

$50.34

-0.03 (-0.06%)

06:05
11/18/19
11/18
06:05
11/18/19
06:05
Periodicals
U.S. to extend license allowing companies to do business with Huawei, NYT says »

The Trump administration…

MU

Micron

$47.70

0.88 (1.88%)

WDC

Western Digital

$50.34

-0.03 (-0.06%)

OCLR

Bought by LITE

$0.00

(0.00%)

ACIA

Acacia Communications

$67.08

0.58 (0.87%)

NPTN

NeoPhotonics

$8.57

0.08 (0.94%)

LITE

Lumentum

$68.91

0.91 (1.34%)

IIVI

II-VI

$29.45

0.19 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 03

    Dec

  • 09

    Dec

  • 09

    Dec

AVEO

Aveo Pharmaceuticals

$0.64

-0.0088 (-1.37%)

06:05
11/18/19
11/18
06:05
11/18/19
06:05
Hot Stocks
Aveo Pharmaceuticals presents new data from Phase 3 TIVO-3 trial of tivozanib »

AVEO Oncology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$23.99

2.5 (11.63%)

06:05
11/18/19
11/18
06:05
11/18/19
06:05
Downgrade
Amarin rating change  »

Amarin downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

WRK

WestRock

$39.50

-0.52 (-1.30%)

06:04
11/18/19
11/18
06:04
11/18/19
06:04
Upgrade
WestRock rating change  »

WestRock upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JCOM

j2 Global

$95.90

1.17 (1.24%)

06:04
11/18/19
11/18
06:04
11/18/19
06:04
Initiation
j2 Global initiated  »

j2 Global initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 04

    Dec

  • 09

    Dec

ELS

Equity Lifestyle

$69.44

0.795 (1.16%)

06:03
11/18/19
11/18
06:03
11/18/19
06:03
Upgrade
Equity Lifestyle rating change  »

Equity Lifestyle upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

KRTX

Karuna Therapeutics

$17.26

-0.26 (-1.48%)

06:02
11/18/19
11/18
06:02
11/18/19
06:02
Hot Stocks
Karuna Therapeutics: KarXT met primary endpoint in Phase 2 trial »

Karuna Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGFEY

Eurobank

$0.00

(0.00%)

06:01
11/18/19
11/18
06:01
11/18/19
06:01
Upgrade
Eurobank rating change  »

Eurobank upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPLK

Splunk

$119.15

2.15 (1.84%)

06:01
11/18/19
11/18
06:01
11/18/19
06:01
Upgrade
Splunk rating change  »

Splunk upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CANG

Cango

$6.79

-0.05 (-0.73%)

06:00
11/18/19
11/18
06:00
11/18/19
06:00
Downgrade
Cango rating change  »

Cango downgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.